bioAffinity Technologies (NASDAQ:BIAF) Posts Quarterly Earnings Results

bioAffinity Technologies (NASDAQ:BIAF) announced its quarterly earnings results on Friday. The company reported ($1.11) earnings per share (EPS) for the quarter, FiscalAI reports. bioAffinity Technologies had a negative net margin of 217.45% and a negative return on equity of 425.87%. The firm had revenue of $1.59 million for the quarter.

bioAffinity Technologies Stock Up 109.7%

NASDAQ BIAF traded up $1.17 during trading on Friday, hitting $2.24. 197,452,210 shares of the company traded hands, compared to its average volume of 4,485,899. bioAffinity Technologies has a 12 month low of $0.69 and a 12 month high of $46.53. The business has a fifty day simple moving average of $1.15 and a 200 day simple moving average of $2.52. The company has a market capitalization of $10.10 million, a P/E ratio of -0.11 and a beta of 2.42. The company has a current ratio of 3.65, a quick ratio of 3.64 and a debt-to-equity ratio of 0.01.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in BIAF. Sabby Management LLC acquired a new stake in bioAffinity Technologies in the 3rd quarter worth approximately $719,000. Scientech Research LLC bought a new position in shares of bioAffinity Technologies in the third quarter valued at approximately $49,000. Finally, Geode Capital Management LLC acquired a new stake in shares of bioAffinity Technologies in the fourth quarter worth $36,000. 1.64% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of bioAffinity Technologies in a research report on Wednesday, January 21st. One analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, bioAffinity Technologies has a consensus rating of “Reduce”.

About bioAffinity Technologies

bioAffinity Technologies, Inc (NASDAQ: BIAF) is a U.S.-based biotechnology company specializing in the development and commercialization of advanced in vitro diagnostic platforms for oncology. Leveraging proprietary bioaffinity and nanotechnology approaches, bioAffinity’s platforms are designed to isolate and analyze cancer-specific biomarkers from blood, tissue, and other biological samples with high sensitivity and specificity. The company’s core technologies aim to enable earlier detection of solid tumors, improved disease monitoring, and more personalized treatment strategies.

The company’s primary product pipeline includes assays targeting breast cancer and other solid tumor indications.